Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS G12C Inhibitor

inhibitors but also provides a starting point for the discovery of inhibitors against other oncogenic KRAS mutants.